A University of Colorado Cancer Center study recently  reports “robust antitumor activity” of the drug TAK-733 in cells and mouse  models of colorectal cancer.

However, in this study, it seemed as if the drug’s path  through the body was uneven. “The drug has had some challenges in development  when used in the context of a real, human body.” says Lieu.  

TAK-733 is a potent and selectiveMEK allosteric site inhibitor for MEK1 with IC50 of 3.2 nM, inactive to Abl1,AKT3, c-RAF, CamK1, CDK2, c-Met, etc. Phase 1.